Mahmoud Ebrahim, Al Mansour Sarah, Bosaeed Mohammad, Alharbi Ahmad, Alsaedy Abdulrahman, Aljohani Sameera, Alalwan Bassam, Alothman Adel
Division of Infectious Diseases, Department of Medicine, King Abdulaziz Medical City - Riyadh, Riyadh, Saudi Arabia.
College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Infect Drug Resist. 2020 Aug 3;13:2667-2672. doi: 10.2147/IDR.S254395. eCollection 2020.
While methicillin-resistant (MRSA) bacteremia has poor outcomes, we describe our experience with Ceftobiprole mainly as a combination therapy for the treatment of MRSA bacteremia. All the cases of MRSA bacteremia in our center at the King Abdulaziz Medical City (KAMC), Riyadh, that had undergone Ceftobiprole treatment were included. We had six cases of MRSA bacteremia between 2018 and 2019, secondary to different infectious syndromes including endocarditis. There was a severe infection that required intensive care unit (ICU) admission in four cases. Ceftobiprole is used in combination with vancomycin in four cases. On day 14, all cases had a favorable outcome with microbiological and clinical improvement. However, three patients died after months of suffering from bacteremia from unrelated causes for the infection. The clinical outcome in our series of treatment of MRSA bacteremia using Ceftobiprole was favorable. Further studies for the evaluation of the use of Ceftobiprole in MRSA bacteremia should be encouraged.
尽管耐甲氧西林金黄色葡萄球菌（MRSA）菌血症的预后较差，但我们描述了我们使用头孢比普的经验，主要是作为治疗MRSA菌血症的联合疗法。纳入了沙特阿拉伯利雅得阿卜杜勒阿齐兹国王医疗城（KAMC）我们中心所有接受过头孢比普治疗的MRSA菌血症病例。2018年至2019年期间，我们有6例MRSA菌血症病例，继发于包括心内膜炎在内的不同感染综合征。有4例严重感染需要入住重症监护病房（ICU）。4例中头孢比普与万古霉素联合使用。在第14天，所有病例在微生物学和临床方面均有改善，预后良好。然而，3例患者在因感染无关原因患菌血症数月后死亡。我们使用头孢比普治疗MRSA菌血症系列的临床结果是良好的。应鼓励进一步研究评估头孢比普在MRSA菌血症中的应用。
